There is no much evidence on the use of levosimendan in cardiac surgery in terms of survival advantage after surgery
Commentary: The quest for the holy grail continues: Is levosimendan the best choice to support patients with cardiomyopathy requiring cardiac surgery?
Onorati, Francesco;Faggian, Giuseppe
2020-01-01
Abstract
There is no much evidence on the use of levosimendan in cardiac surgery in terms of survival advantage after surgery
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Commentary JTCVS 2020 Levosimendan.pdf
non disponibili
Tipologia:
Versione dell'editore
Licenza:
Accesso ristretto
Dimensione
113.82 kB
Formato
Adobe PDF
|
113.82 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
